Overview

Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

Status:
Active, not recruiting

Trial end date:
2022-06-07

Target enrollment:

Participant gender:

Summary

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non-valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this post-authorization safety study (PASS) to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other drug related adverse events) of edoxaban use in patients with NVAF who were not preselected.

Details

Lead Sponsor:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Collaborators:

Hippocrates Research
IMS Health
ITEC Services
Quintiles, Inc.
SSS International Clinical Research GmBH

Treatments:

Edoxaban